Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 63

Spheroids vs. Organoids—A Data-Driven Approach for 3D Culture Model Selection

In this October 13 Learning Lab, Hilary Sherman, a Senior Scientist in the Corning Life Sciences Applications Lab, and Robert Padilla, a Field Application Scientist at Corning, dive into the topic of 3D culture techniques and why these technologies should be a part of any researcher’s repertoire.

Three-dimensional (3D) cultures such as spheroids and organoids are an important part of the research model market, helping to close the gap between cell cultures and animal models. Both organoids and spheroids have been used to create in vivo-like tissue models of cancer subtypes to study novel therapies and to make models for tissue engineering and regenerative medicine studies. But there are some key differences, with important implications for various applications. The right tool for a project is not always obvious. For spheroids and organoids, knowing where the cultures are similar and where they differ will help scientists select the best resource for their projects the first time around.

Robotic cup helps wheelchair users stay hydrated

Mobility impairments such as those caused by cerebral palsy make it hard for people to perform even simple tasks like drinking a sip of water.

Gary Lynn, a Houstonian living with the condition, turned to Rice University’s Oshman Engineering Design Kitchen (OEDK) for help making the idea of an assistive-drinking device a reality. Rice undergraduate engineering students Thomas Kutcher and Rafe Neathery rose to the challenge, and the result is RoboCup ⎯ a robotic device that enables people with limited mobility to stay hydrated without help.

“We wanted to make it possible for people with cerebral palsy or similar mobility challenges to drink water autonomously rather than needing to rely on caregiver assistance,” said Kutcher, who is a bioengineering major. “The device is designed for wheelchair users who might have trouble holding a cup, and our hope is that it will grant users greater freedom.”

Humanity in 2050

👉For business inquiries: [email protected].
✅ Instagram: https://www.instagram.com/pro_robots.

In the quest to overcome the limitations of the human body and mind, scientists worldwide are diligently working on various technologies. The question arises: What will human beings become after undergoing numerous enhancements? Will we retain our identity while embracing the possibilities offered by artificial intelligence? What extraordinary capabilities will biotechnology bestow upon us? And how will our emotions and desires evolve as our bodies undergo transformation?

Join us on a captivating journey to the year 2050, as we delve into the frontiers of scientific research, consult with visionary futurists, and examine the predictions of brilliant minds. Together, we will explore the profound changes that lie ahead!

00.00 — Introduction.
01:15 — Matrix-Like Innovation: Baby-Growing Factories Bring Science Fiction to Reality.
02:33 — The Future of Longevity: Exploring Eternal Youth Technologies.
03:51 — Unlocking Superpowers: Genetic Engineering Takes Humans and Animals to New Heights!
05:11 — Brain Implants in 2050: The Future of Communication, Control, and Enhanced Human Abilities.

Redefining Human Life.
In the year 2050, the human body will undergo a transformation like never before. For the first time in our 300,000-year history, evolution will not solely rely on natural selection but rather on deliberate re-engineering through technology.

Revolutionary Childbirth.

Continue reading “Humanity in 2050” | >

With first-in-human trial results, Intellia shows the world that gene editing has arrived

All medical breakthroughs have to start somewhere, and Intellia Therapeutics is ready to show the world the first-in-human gene editing data that could be the start of a | Interim results are in for Intellia and partner Regeneron’s in vivo CRISPR/Cas9 genome editing candidate, NTLA-2001, in patients with transthyretin (ATTR) amyloidosis: and the numbers look good. This is the first time gene editing has been proven to work in humans, which “opens up a whole new area of therapies for patients that wasn’t there.”

Nano-mechanoelectrical approach increases DNA detection sensitivity by 100 times

UMass Amherst researchers have pushed forward the boundaries of biomedical engineering one hundredfold with a new method for DNA detection with unprecedented sensitivity.

“DNA detection is in the center of bioengineering,” says Jinglei Ping, lead author of the paper that appeared in Proceedings of the National Academy of Sciences.

Ping is an assistant professor of mechanical and , an adjunct assistant professor in and affiliated with the Center for Personalized Health Monitoring of the Institute for Applied Life Sciences. “Everyone wants to detect the DNA at a low concentration with a high sensitivity. And we just developed this method to improve the sensitivity by about 100 times with no cost.”

Dr. Alex Colville, Ph.D. — Co-Founder and General Partner — age1

Venture Investing To Catalyze The Next Generation Of Founder-Led, Longevity Biotech Companies — Dr. Alex Colville, Ph.D., Co-Founder and General Partner — age1.

Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 (https://age1.com/), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases.

With a recent initial closing of US$35 million, age1 will be focusing on founders and companies at the earliest stages of first-money in, pre-seed and seed funding, and is resourced to continue to support companies through later rounds.

Dr. Colville previously established the biotech arm of Starbloom Capital and served as founding Chief of Staff of Amaranth Foundation, where he led: the foundation’s support of skilled researchers and ambitious moonshot projects in the longevity field, and helped to advance their lobbying efforts; the TIME Initiative (a group with mission to activate undergraduate students’ interest in aging biology); the Marine Biology Laboratory Biology of Aging Summer Course, among other programs.

Dr. Colville completed his Ph.D. in Genetics at Stanford University studying the biology of aging in Dr. Thomas Rando’s lab while consulting for several family offices, the R&D team of Rubedo Life Sciences, and the business development team of Maze Therapeutics. Prior to his Ph.D., while at Northeastern University completing his Bachelor of Science (B.S.) in Chemical Engineering with a Minor in Biochemical Engineering, he advised pharma companies as a management consultant at Putnam Associates, a boutique life sciences consulting firm.

Continue reading “Dr. Alex Colville, Ph.D. — Co-Founder and General Partner — age1” | >

“Inverse vaccine” shows potential to treat multiple sclerosis and other autoimmune diseases

A typical vaccine teaches the human immune system to recognize a virus or bacteria as an enemy that should be attacked. The new “inverse vaccine” does just the opposite: it removes the immune system’s memory of one molecule. While such immune memory erasure would be unwanted for infectious diseases, it can stop autoimmune reactions like those seen in multiple sclerosis, type I diabetes, or rheumatoid arthritis, in which the immune system attacks a person’s healthy tissues.

The inverse vaccine, described in Nature Biomedical Engineering, takes advantage of how the liver naturally marks molecules from broken-down cells with “do not attack” flags to prevent autoimmune reactions to cells that die by natural processes. PME researchers coupled an antigen — a molecule being attacked by the immune system— with a molecule resembling a fragment of an aged cell that the liver would recognize as friend, rather than foe. The team showed how the vaccine could successfully stop the autoimmune reaction associated with a multiple-sclerosis-like disease.

“In the past, we showed that we could use this approach to prevent autoimmunity,” said Jeffrey Hubbell, the Eugene Bell Professor in Tissue Engineering and lead author of the new paper. “But what is so exciting about this work is that we have shown that we can treat diseases like multiple sclerosis after there is already ongoing inflammation, which is more useful in a real-world context.”

Longevity Summit Dublin

The last 2 questions and the answers are great. The first starts at 30 minutes. And I like his answer to the 2nd question especially, the time is 33:54. “What is giving me great hope is that we’re entering the phases where we have more than enough tools to get really get close to escape velocity.”

Genome Engineering for Healthy Longevity – George Church at Longevity Summit Dublin 2023.

#GeorgeChurch #GenomeEngineering #HealthyLongevity #LongevitySummitDublin2023 #AgingResearch #DublinConference #LongevityScience #BiomedicalEngineering #GeneticModification #DublinTalks #GenomicInnovation #MedicalScience #LongevityResearch #PrecisionMedicine #AgingInterventions #Healthspan #GenomeEditing #AntiAging #LongevityInsights #Genetics #Innovation

Examining the genesis of CRISPR’s molecular scissors

Genome engineering may be the future of medicine, but it relies on evolutionary advances made billions of years ago in primordial bacteria, the original masters of gene editing.

Modern day genome engineers like Columbia’s Sam Sternberg are always looking forward, modifying these ancient systems and pushing them to perform ever more complex feats of gene editing.

But to uncover , it sometimes pays to look backward in time to understand how bacteria first created the original systems, and why.

Newly engineered CRISPR enzyme for editing DNA could improve patient treatment

A new CRISPR-based gene-editing tool has been developed which could lead to better treatments for patients with genetic disorders. The tool is an enzyme, AsCas12f, which has been modified to offer the same effectiveness but at one-third the size of the Cas9 enzyme commonly used for gene editing. The compact size means that more of it can be packed into carrier viruses and delivered into living cells, making it more efficient.

Researchers created a library of possible AsCas12f mutations and then combined selected ones to engineer an AsCas12f with 10 times more editing ability than the original unmutated type. This engineered AsCas12f has already been successfully tested in mice and has the potential to be used for new, more effective treatments for patients in the future.

By now you have probably heard of CRISPR, the gene-editing tool which enables researchers to replace and alter segments of DNA. Like genetic tailors, scientists have been experimenting with “snipping away” the genes that make mosquitoes malaria carriers, altering food crops to be more nutritious and delicious, and in recent years begun to overcome some of the most challenging diseases and genetic disorders.

/* */